Table 1 Patient characteristics
Total (n = 180) | Rituximab exposed (n = 52) | Rituximab unexposed (n = 128) | |
|---|---|---|---|
Demographics | |||
Female, n (%) | 129 (71.7) | 43 (82.7) | 86 (67.2) |
Age, median (IQR) | 13.0 (10.0, 15.0) | 13.0 (10.0, 16.0) | 12.5 (9.0, 15.0) |
Caucasiana, n (%) | 72 (48.9) | 14 (29.8) | 58 (58.0) |
Region, n (%) | |||
Northeast | 29 (16.1) | 9 (17.3) | 20 (15.6) |
Midwest | 29 (16.1) | 8 (15.4) | 21 (16.4) |
South | 98 (54.4) | 30 (57.7) | 68 (53.1) |
West | 24 (13.3) | 5 (9.6) | 19 (14.8) |
Systemic lupus erythematosus, n (%) | 2 (1.1) | 2 (3.9) | 0 (0.0) |
Sjögren syndrome, n (%) | 1 (0.6) | 1 (1.9) | 0 (0.0) |
ICU status, n (%) | 31 (17.2) | 11 (21.2) | 20 (15.6) |
Length of stay (days), median (IQR) | 6 (3.0, 12.0) | 7.0 (3.0, 17.0) | 6.0 (3.0, 11.0) |
Primary outcome | |||
Re-hospitalization in 12 months, n (%) | 66 (36.7) | 20 (38.5) | 46 (35.9) |
Secondary outcomes | |||
Length of re-hospitalization (days), median (IQR) | 3.0 (1.0, 5.0) | 2.0 (1.0, 4.0) | 4.0 (2.0, 6.0) |
Time to re-hospitalization (days), median (IQR) | 365 (138, 365) | 365 (138, 365) | 365 (137, 365) |